The Eyquem lab is a highly collaborative group passionate about using synthetic immunology to advance adoptive cell therapies.

Our Research

Our laboratory is aimed at understanding the current limitations of CAR T cell therapy using innovative tumor models and functional genomics and overcoming these challenges by reprogramming T cells with the use of genome editing and synthetic receptors.

Our Partners

Our People

The Eyquem lab is a highly collaborative group passionate about using synthetic immunology to advance adoptive cell therapies.

News

Media highlights of Eyquem Lab's research.

Peptide-mediated CRISPR engineering of cells

Peptide-RNP delivery paper highlighted by Nature Biomedical Engineering

HIT-T cell paper highlighted in Cancer Cell

Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors

AACR 2018: An off-the-shelf, dual-targeted CAR T-cell product showed promising results in preclinical studies

CRISPR gene therapy is enhancing t-cell immnotherapy treatment of cancer and treatments in people could be available within 2 to 3 years

Curing Cancer with CRISPR

Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors

Pancreatic cancer cells digest extracellular protein

CRISPR-driven CARs

Using CRISPR to Supercharge Cancer-Killing Immune Cells

Stay Updated

Keep up-to-date with the latest research from the Eyquem lab.

Follow us on Twitter

Sign up for Newsletter

Recent Lab News

June 2021

Joe Muldoon was selected for the Cancer Research Institute Irvington Postdoctoral Fellowship

December 2020

Vincent Allain was selected for the ARC foundation International Mobility Award

August 2020

William Nyberg was selected for the Swedish Society for Medical Research fellowship

December 2019

Alexis Talbot was selected for the Fondation de France Fellowship